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Summary
Hypoalbuminaemia and thrombocytopaenia are two clinical problems frequently encountered in patients with
chronic liver failure or cancer following treatment with chemotherapy. The current study was designed to assess the
magnitude and duration of thrombopoietin and albumin transgene expression hoping to increase the production of
albumin and platelets. Immunocompetent and immunocompromised (nude) mice were injected intramuscularly
with plasmids expressing either human serum albumin or human thrombopoietin. The therapeutic expression
cassette of the plasmids was driven by either CMV or elongation factor 1-alpha promoters respectively. In order to
achieve muscle specific expression both gene constructs included the myosin light chain enhancer. The experiment
was conducted in a group of mice which were injected with the transgene plasmid either in normal saline or plasmid
followed by electroporation, ultrasound, optison and a combination of all three to increase transgene expression.
The result showed that plasmids with the CMV promoter induced the highest transgenic expression lasting for one
week whilst plasmids with the elongation factor 1-alpha promoter produced a weaker expression lasting for a
longer and more stable duration of expression up to 3 months in both immunocompetent and nude mice. The
combination of electroporation and ultrasound with Optisonä  provided the highest transgene expression. We
concluded that it would be possible to increase albumin and platelets production by an intramuscular injection of
plasmids expressing human albumin and thromopoietin. A combination of electroporation and ultrasound with
Optisonä  can increase their expression.
I. Introduction
Albumin produced exclusively by liver is the most
important factor in regulation of plasma volume and tissue
fluid balance. It also binds to and transports a range of
lipid and lipid-soluble substances. Hypoalbuminaemia
commonly secondary to chronic liver disease can result in
clinically ascites and peripheral oedema.
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Thrombopoietin (TPO) is a cytokine produced by
liver and involved in the regulation of platelets production.
The receptor for TPO is c-Mpl. The proto-oncogene c-mpl
is a member of cytokine receptors superfamily with a
similar sequence to erythropoietin and granulocyte colony-
stimulating factor (G-CSF) receptors (Souyri et al, 1990;
Gisselbrecht and Souyri, 1992). Expression of c-mplin
normal mice appears to be restricted to haematopoietic
stem cells, megakaryocytes, and platelets although low
levels of expression have been detected in endothelial cells
(Gisselbrecht and Souyri, 1992; Methia et al, 1990). The
TPO level decreases significantly in chronic liver diseases.
Skeletal muscle has previously been shown to
express the encoded proteins in quantities sufficiently
enough to generate immune responses following its
introduction of naked plasmid DNA (Wolff et al, 1990;
Ulmer at al, 1993; Hasan et al, 1999). The potential
usefulness of skeletal muscle for local expression (Miller
et al, 1995; Alila et al, 1997; Novo et al, 1997) and
systemic delivery of therapeutic proteins has been
explored (Raz et al, 1993; Raz et al, 1995; Fazio et al,
1994; Ma et al, 1995; Levy et al, 1996; Tripathy et al,
1996; Tokui et al, 1997; Aihara and Miyazaki, 1998;
Anwer et al, 1998; Nitta et al, 1998; Horton et al, 1999).
Although muscle lacks the cellular machinery necessary
for regulated protein secretion, muscle cells appear to be
able to utilise a constitutive secretory pathway to release
heterologous proteins.
Direct in vivo transfer of the gene encoding
erythropoietin via transduction by plasmid DNA (Rizzuto
et al, 2000; Maruyama et al, 2001; Vilalta et al, 2001), or
adenoviral and adeno-associated vectors (Osada et al,
1999; Bohl et al, 2000; Maione et al, 2000; Rudich et al,
2000; Yan et al, 2000), has shown to be effective in
replacing repeated systemic administrations of
recombinant human erythropoietin in the management of
anaemia due to decreased red blood cell production
(Rudich et al, 2000; Maione et al, 2000; Osada et al,
1999).
In this study the feasibility of expressing TPO and
albumin after appropriate plasmid injection into mouse
skeletal muscle are investigated by giving constructs
containing the human albumin gene and human TPO gene
respectively both into immunocompetent and
immunocompromised animals. This provides an
alternative extra-hepatic site for promoting and enhancing
expression of proposed therapeutic genes for TPO or
albumin production.
The aim of this study was to develop a system that
can be utilized clinically for increasing albumin levels to
treat patients with hypoalbuminaemia, and thrombopoietin
(TPO) to treat thrombocytopaenia by using the CMV and
the elongation factor 1-alpha (EF1a ) promoters and the
myosin lightchain (Souyri et al, 1990; Methia et al, 1990)
enhancer (Rosenthal et al, 1989). The inclusion of the
latter in the gene constructs has been shown to not only
increase expression, but also to result in muscle specific
expression (Novo et al, 1997). In this way the site of
therapeutic protein secretion was limited to a secure
environment. Electroporation, ultrasonic cavitation and
potentiation with Optisonä  (Mallinckrodt Medical Ltd.,
Northamtpon, UK) were used to augment the magnitude of
TPO and albumin gene expression (Yamashita et al,
2002).
II. Materials and methods
A. Plasmids
Plasmids were constructed to express either a.) human
thrombopoietin (hTPO), or b.) human albumin (hAlb) genes.
Two different promoters were used to drive the gene cassettes;
either the CMV promoters (pGT123TPO and pGT123hAlb) or
the EF1a  promoters (pDERMhTPO and pDERMhAlb).
PGTalb and the pGThTPO were based on the pGT vector
produced by InvivoGen (San Diego, CA, USA) with CMV
promoter and myosin lightchain 1 and 3 MLC sequence
enhancer. The pDERMhTPO and pDERMhALB had EF1a
promoter and a myosin enhancer. The transgene in the pDERM
plasmids was preceded by 5’UTR Glut1. Both plasmids were
grown in E.coli.
Quality control data showed OD 260/280:1.91-%
supercoiled DNA: >95%-RNA was not detectable on agarose
gel-toxin assay <0.1 EU/m g plasmid, less than 2% protein.
Sterility test showed no colony forming units in a bioburden
assay.
B. Murine models
Immunocompetent (Balb C) and immunocompromised
nude (CD-1) mice were used. BALB/c mice were bred in the
animal facility of the Palacky University, Olomouc, Czech
Republic. Female mice aged 10 - 14 weeks and weighing 20 -
24g were used in the experiments. They were maintained in a 12
hours light/dark cycle at a temperature of 20 - 24 ° C and fed with
standard diet and water ad libitum in accordance with the
National Institutes of Health guidelines for animal care.
Immunocompromised CD-1 mice were maintained under
pathogen free conditions at the same institution and under the
same regimen. Female CD-1 mice aged 8-10 weeks and
weighing 17-21g were used in the experiment.
C. Plasmid administration
Plasmids were injected intramuscularly in the tibialis
anterior of both hind-legs at a dose of 50m g f plasmid per mouse
in 50m l of saline.
D. Transfection
Th  following methods were employed in order to increase
gene uptake and expression after intramuscular plasmid
administration:
1. Electroporation
Electric pulses were delivered using pulse generator
Electro Square PoratorTM ECM 830 (BTX, Genetronics Inc., San
Diego, CA, USA). The pulses were delivered using a 2-needle
array inserted into the muscle. The distance between electrodes
(needles) was 5 mm. The following protocol was used: 8 pulses,
voltage 200V/cm, 40 ms duration of the pulse.
2.Ultrasound
Ultrasound machine, Sonitron 1000 (Rich-Mar
Corporation, Inola, Oklahoma, USA) was used. The probe was
applied at the side of injection. Ultrasound with 1MHz frequency
was applied for 2 minutes using 2 Watts of power and operated at
20% of duty cycle.
Optisonä  (Mallinckrodt Medical Ltd., Northamtpon, UK)
was added to potentiate cavitation of ultrasound. When Optisonä
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was used, it was added to the plasmid solution at a ratio of 2:5.
The plasmid in saline and Optisonä  (28%) were injected
together.
3. Anaesthesia
Plasmid delivery, as well as ultrasound and electroporation
application, was administered under general anaesthesia. A
combination of Hypnorm (fentanyl/fluanisone) and Hypnovel
(midazolam) (F. Hoffmann/La Roche Ltd., Basel, Switzerland).
Hypnorm, Hypnovel and sterile water for injection were mixed
1:1:2. Animals were injected in the peritoneal cavity with 0.005
ml of this solution per 1g of mouse weight. After taking blood
samples animals were sacrificed.
E. Experimental design
Control animals (group 1, n=36) were injected with normal
saline or with plasmid only. Plasmid TPO or plasmid albumin in
normal saline were injected into group 2 mice (n=36). A further
group (group 3, n=36) of animals received each plasmid in
normal saline followed by electroporation, and group 4 animals
(n=36) received plasmid in saline followed by ultrasound. In
group 5 (n=36) was plasmid application followed by both,
ultrasound and immediately after ultrasound with electroporation
and group 6 (n=36) mice received plasmid in saline mixed with
Optisonä  and as in group 5 in these animals was plasmid
application followed by electroporation and ultrasound.
All mice were given a once only injection and 0.5 ml of
blood was withdrawn. Then animals were sacrificed at 1, 2, 3 and
4 weeks, and at 3 and 6 months.
Plasmids used were pGT123hTPO with CMV promoter
plus MLC enhancer, pDERMhTPO with EF1a  promoter plus
MLC enhancer, pGT123hAlbumin with CMV promoter plus
MLC enhancer and pDERMhAlbumin with EF1a  promoter.
F. Levels of hTPO
For the study of serum TPO the ELISA TPO (Human TPO
Quantikine Colorimetric Sandwich ELISA, R&D Systems
Europe Ltd., Abingdon, UK) assay was used. This employs the
quantitative sandwich enzyme immunoassay technique. A
monoclonal antibody specific for TPO was pre-coated on to the
microplate. Standards and samples were pipetted into the wells
and the immobilised antibody bound any TPO present. After
washing away any unbound substances, an enzyme-linked
monoclonal antibody specific for TPO was added to the wells.
Following a wash to remove any unbound antibody-enzyme
reagent, substrate solution was added to the wells and colour
developed in proportion to the amount of TPO bound in the
initial step. The colour development was stopped and intensity of
colour was measured.
G. Levels of hAlb
All reagents, including microtitre plates and Human
Albumin ELISA (E80-129, Bethyl Laboratories Inc.,
Montgomery, USA) quantitation kit, were obtained from Bethyl
Laboratories Inc., Montgomery, Texas 77356, USA. All
incubations were performed at room temperature. Microwells
were first incubated for 1 hr with 100 m l of affinity purified
uman albumin capture antibody diluted 1/100 in carbonate
buffer (0.05 M sodium carbonate, pH 9.6). After incubation, the
capture antibody was removed and the wells were washed twice
with Tween 20, 0.05% in TBS-Tris buffered saline, (50 mM Tris,
0.14 M NaCl, pH 8.0). Wells were then incubated with 200 m l of
postcoat solution (TBS containing 1% BSA-bovine serum
albumin) for 30 minutes. After incubation wells were washed
two times as above.
Standards and samples were diluted in sample diluent
(TBS, containing 0.05% Tween 20, 1% BSA) and transferred to
predetermined wells and incubated for 1hr. Wells were then
washed twice and 100 m l of HRP (horseradish peroxidase)-
conjugated human albumin detection antibody, diluted 1/35000,
was added. After incubation for 1hr the wells were washed 3
ti es.
Albumin was detected by addition of 100 m l of TMB (3,3’,
5,5’-tetramethyl benzidine) substrate. The reaction was stopped
with 2 M H2SO4 and the optical density was measured at 450 nm.
H. Statistical analyses
Standard Student’s T-test was used for statistical analyses
of measurements to compare the control with each injected
group.
III. Results
A. Plasmids with the CMV promoter
pGT123hTPO administered with ultrasound and
el ctroporation to nude mice resulted in a steep rise in
serum hTPO expression at week 1 (1010 ± 1440 pg/ml,
mean ± SD, p < 0.05), but the level decreased to 58 pg/ml
at week 2, 54 pg/ml at week 3 and 30 pg/ml at week 4
(Table 1). However, there was no statistically significant
change in platelet count when compared with the control.
Table 1. Human thrombopoietin levels in serum of treated animals. Immunocompromised mice were injected
intramuscularly with 50 m g of plasmid pGT123hTPO containing TPO with CMV promoter. Results (in ng/ml) are shown
as mean ± SD. p value was calculated against control group each week.
Week 1
(n=6)
Week 2
(n=6)
Week 3
(n=6)
Week 4
(n=6)
Simple plasmid injection I.M
(Group 2, n=36)
68.7 ± 53
(p<0.05)
56.3 ± 32
(NS)
39 ± 13
(NS)
61 ± 18
(NS)
I.M. injection plus electroporation
(Group 3, n=36)
175.3 ± 261
(NS)
52.5 ± 18
(NS)
183.7 ± 248
(p<0.05)
8 ± 11
(NS)
I.M. injection plus ultrasound
(Group 4, n=36)
430 ± 523
(p>0.05)
37.3 ± 43
(NS)
17.7 ± 17
(NS)
15.3 ± 19
(NS)
I.M. injection plus ultrasound and
electroporation (Group 5, n=36)
1010 ± 1440
(p<0.05)
58 ± 74
(NS)
54 ± 62
(NS)
30 ± 14
(NS)
Control
(Group 1, n=36)
6 ± 8 35 ± 49 10 ± 14 14 ± 20
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I.M., intramuscular
Group 1 – control group mice were injected with pGT123hAlb plasmid intramuscularly.
Group 2 – treated with intramuscular plasmid injection of 50 m g per mouse into both tibialis anterior muscles.
Group 3 – treated with intramuscular plasmid injection of 50 m g per mouse followed by electroporation (8 pulses, 200 V/min, duration of
pulse 40 ms).
Group 4 – treated with intramuscular plasmid injection of 50 m g per mouse followed by ultrasounds application (2 min., 2 W, 1 MHz).
Group 5 – treated with intramuscular plasmid injection of 50 m g per mouse followed by both ultrasound 2 min., 2 W, 1 MHz) and
electroporation (8 pulses, 200 V/min, duration of pulse 40 ms).
Table 2. Human albumin levels in serum of treated animals. Im unocompetent mice were injected with 50 m g of
plasmid pGT123hAlb, containing human albumin. Results (in ng/ml) are shown as mean ± SD. pvalue was calculated
against control group each week.
Week 1
(n=6)
Week 2
(n=6)
Week 3
(n=6)
Week 4
(n=6)
I.M. injection of pGT123hAlb
(Group 2, n=36)
9 ± 11
(p<0.0001)
0 0 0
I.M. injection of pGT123hAlb
with
OptisonTM, ultrasound
and electroporation
(Group 6, n=36)
377 ± 100
(p<0.0001)
0 0 0
Control
(Group 1, n=36)
0 0 0 0
Group 1 – treated with intramuscular plasmid injection of 50 m g per mouse into both tibialis anterior muscles.
Group 2 – treated with intramuscular injection of pGT123hTPO plasmid.
Group 6 – treated with intramuscular injection of 50 m g of plasmid mixed with 20 m l Optisonä  per mouse, followed by ultrasound (2
min., 2 W, 1 MHz) and electroporation (8 pulses, 200 V/min, duration of pulse 40 ms).
Zero means that albumin concentration was bellow the detectable level of ELISA test.
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Table 3. Serum levels of human thrombopoietin in mice, treated with pDERMhTPO plasmids. 50m g PDERMhTPO
and 20 m l Optisonä  was injected per mouse. Ultrasound (2 min., 2 W, 1MHz) and electroporation (8 pulses, 200 V/min,
duration of pulse 40 ms) were applied at the site of injection. Control mice were injected with pDERMhAlb plasmid which
does not contain human TPO. Results (in pg/ml) are shown as mean ± SD. p value was calculated against control group on
each occasion.
2 weeks 1 month 3 months 6 months
Balb/C Mice
(immunocompetent)
Treated
Group 6, (n=36)
105 ± 107
(p<0.03)
89.3 ± 122
 (p<0.05)
47.8 ± 77
(NS)
134 ± 87
(p<0.01)
Control
Group 1, (n=36)
8.3 ± 19 8.8 ± 19 21.7 ± 32 31 ± 26
CD 1 Mice
(immunocom-
promised)
Treated Group 6,
(n=36)
168 ± 78
(p<0.002)
70.2 ± 54
(p<0.01)
70.8 ± 75
(p<0.04)
250 ± 179
(p<0.01)
Control
Group 1, (n=36)
23 ± 49 7.3 ±18 8.8 ± 11 30 ± 28
Group 1 – treated with intramuscular plasmid injection of 50 m g per mouse into both tibialis anterior muscles.
Group 6 – treated with intramuscular injection of 50 m g of plasmid mixed with 20 m l Optisonä  per mouse, followed by ultrasound (2
min., 2 W, 1 MHz) and electroporation (8 pulses, 200 V/min, duration of pulse 40 ms).
The same procedure was performed with plasmid
pGT123hAlb. Here, transgene expression was only
detectable in the serum when the echo-contrast agent was
added to the plasmid solution and a combination of
electroporation and ultrasound were employed. Then the
serum level of hAlb in immunocompetent mice was
significantly increased at one week (377 m g ± 100, mean ±
SD, p <  0.0001) (Table 2).
The procedures indicated that transgene expression
for serum hTPO or hAlb was highest with the combination
of electroporation, ultrasound and Optisonä , used
concomitantly.
B. Plasmids with EF1a  promoter
hTPO levels rose to 105 pg/ml ( p < 0.03) in
immunocompetent and 168 pg/ml (p < 0.002) in nude
mice at week 2. Although this was less than expression
seen with the CMV promoter, the duration of expression
lasted for 6 months in both classes of mouse. Again there
was no statistically significant change in platelet count
throughout the experiments when compared with the
control (Table 3).
IV. Discussion
This study has shown that both CMV and EF1a
promoter MLC enhancer based plasmids expressed human
TPO and human albumin in the serum of both
immunocompetent and immunocompromised mice. The
duration of expression was greater with the CMV
promoter compared to the EF1a  promoter, but expression
was short-lived and the level had dramatically decreased
by the second week after administration of the plasmid.
The EF1a  promoter had weaker expression than with
CMV, but continued until the sixth month.
Expression was essentially the same whether the
plasmids were injected in immunocompetent or
immunocompromised animals. This showed that
expression was not related to the immune status of the
animal, but to the type of promoter used. The duration of
expr ssion is of clinical importance as the effect of
recombined human albumin lasts only 2 or 3 days and
patients require repeat administrations two of three times
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per week. Similarly, patients with thrombocytopaenia and
bleeding receive repeated platelet transfusions every 12 to
24 hours.
Other studies have elegantly shown the feasibility of
an intramuscular gene therapy approach. Baumgartner and
colleagues (Baumgartner et al, 1998) showed clinical
improvement of blood flow in patients with peripheral
vascular disease by injection of plasmid encoding vascular
endothelial growth factor (VEGF). This promoted
collateral vessel development in patients with critical limb
ischaemia. Wang et al. (1998) demonstrated the induction
of antigen specific cytotoxic T lymphocytes in humans by
a malarial DNA vaccine.
It is advantageous to incorporate the muscle specific
MLC enhancer in plasmids used with naked DNA or viral
vectors as it increases expression in mature muscle fibres
(Novo et al, 1997) and results in muscle specific
expression (Rosenthal et al 1989) minimising the
theoretical risk of possible harm in the event of integration
and activation in germ cells.
Various techniques have been devised to resolve the
problems related to low transfection efficiency, and safety
in gene therapy. Therapeutic ultrasound was developed to
induce cell membrane permeability. Ultrasound irradiation
has been shown to increase the transfection efficiency of
naked plasmid DNA into skeletal muscle cells especially
with the use of Optisonä . Electron microscopy
demonstrated the transient formation of holes (less than
5m M) in the cell surface with this system, which might
explain the rapid migration of the transgene into the cells.
Taniyama et al. (2002) have shown that transfection of
hepatocyte growth factor plasmid by the ultrasound-
Optisonä  method could be useful for safe clinical gene
therapy to treat peripheral arterial disease without a viral
vector.
Electroporation is another gene delivery method for
non-viral gene therapy in multiple tissues (Heller et al,
1996; Mir et al, 1999). Several groups have observed a 2 -
3 log increase in the level of gene expression after
transfection of reported gene in the muscle by
electroporation (Heller et al, 1996; Mir et al, 1999). Li et
al. (2002), have shown regression of tumours by g -
interferon electroporation gene therapy in mice.
One of the major problems using non-viral delivery
approach is the short duration of transgene expression. For
effective gene therapy of chronic disease, sustained
transgene expression at therapeutic levels is required. The
loss of transgene expression may be due to loss of the
vector, transcriptional silencing of the transgene promoter,
loss of the transfected cell through cell turnover, or the
generation of an immune response to the transgene
product or the transfected cell itself. The majority of pre-
clinical and clinical studies have used strong viral
promoters such as the CMV enhancer/promoter to achieve
high levels of gene expression. Gill et al., (2001) have
shown transient transgene expression with CMV, RSV and
SV40 promoters. However, this showed that the use of the
promoters from the human polybiquitin C (UbC) and the
EF1a  genes resulted in sustained gene expression in the
mouse lung. The UbC promoter directed high level
reporter activity, which was maintained for up to 8 weeks
and was still detectable six months after a single
administration. The results of our study using EF1a
promoter support their findings.
Using a different system, Chow et al. showed long-
term tissue specific gene expression using locus control
region within replicating episomal plasmid and cosmid
vectors (Chow et al, 2002). Locus control regions (LCRs)
re transcriptional regulatory elements, which process a
dominant chromatin remodelling and transcriptional
activating capability conferring full physiological levels of
expression on a gene linked in sis, when integrated into the
ho t cell genome. Using the human b -globin LCR (bLCR)
as a model Chow et al., showed that this class of control
el ment can drive high levels of tissue specific gene
expression in stable infected cultured cells from within an
Epstein-Barr virus-based plasmid (Chow et al, 2002).
LCRs are tissue-specific regulatory elements, which
poss ss powerful chromatin remodelling capability and are
able t  establish and maintain a transcriptional competent,
open chromatin domain, which leads to a sustained level
of transgene expression. Therefore, inclusion of such
elements is able to counteract the cell’s selective gene
silencing mechanism.
Another reason for the transient expression of
plasmid DNA vectors could be due to immunostimulatory
properties of plasmid DNA. Bacterial DNA and bacterially
derived pDNA have the expected mathematical frequency
of CpG dinucleotides and the DNA is predominantly
unmethylated (Kreig 1999). Recognition of these
differences by the host leads to a pleiotropic inflammatory
response that includes the activation of B cells,
mo ocytes, macrophages, dendritic cells, and natural killer
c lls (Krieg et al, 1995; Klinman et al, 1996; Ballas et al,
1996; Sparwasser et al, 1997; Sparwasser et al 1998).
Yew et al, (2002) have shown that CpG-depleted
plasmid DNA vectors have enhanced safety and long term
g ne expression n vivo. This was achieved by reduction of
CpG content of pDNA vectors by replacing large portion
of vector with synthetic, non-CpG sequence.
The longevity of expression was related to sequence
changes made within the CMV enhancer/promoter that
somehow rendered the promoter insensitive to inactivation
over time (Yew et al, 2002). Other promoters appear to
have greater longevity, such as the ubiquitin promoter or
liver-specific promoters, may be more resistant to any
possible inflammation-induced inactivating factors (Qin et
al, 1997; Herweijer et al 2001; Yew et al, 2001)
In this study the ultrasound option with Optisonä
and electroporation increases expression significantly from
ng/l or pg/ml up to m g/l or ng/ml. However, the 2 - 3 log
i cr ase was not sufficient to reach clinical efficacy.
Probably 3 - 6 log increase is needed to achieve clinical
eff cacy.
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